Akademik Veri Yönetim Sistemi
Karagöz M. F., Magnı P.(Yürütücü)
TÜBİTAK - AB COST Projesi , 2022 - 2026
The latest epidemiological data suggest that cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality worldwide. In order to improve the CVD outcomes, we need new strategies that incorporate the complex interplay of different driving forces behind atherosclerosis pathophysiology in addition to the traditional risk factors. AtheroNET aims to consolidate and connect experts from different fields into European and international network that will focus on the use of multiple omics technologies and data integration through machine learning/artificial intelligence ML/AI approach to bring novel paradigms in prevention, diagnosis, and treatment of atherosclerotic cardiovascular disease (ASCVD). Current CVDrelated initiatives and networks are focused on specific aspects of CVD and/or specific methodologies. AtheroNET offers a comprehensive environment in which different stakeholders (basic scientists, clinicians, bioinformaticians, industry representatives, patients’ representatives) will address current challenges by: Organizing multi-centric studies for cross-validation of different genomic, transcriptomic, proteomic, and metabolomics traits related to atherosclerosis; Fostering joined research efforts through different European funds to investigate novel pathophysiological mechanisms, prognostic, diagnostic, and therapeutic ASCVD targets; Inter-sectorial cooperation with the private sector to commercialize novel scientific achievements and secure their delivery to the market; Organizing inter-laboratory dialogs and ring trials leading to standardization and harmonization of different wet-lab and dry-lab workflows; Utilizing specific ML/AI algorithms for data integration and design of innovative multiomics models. Through the abovementioned steps, the Action will train the next generation of scientists ready to tackle upcoming challenges and provide opportunities for the transfer of novel omics technologies from bench to the bedside.
Specific Objectives:
To achieve the main objective described in this MoU, the following specific objectives shall be accomplished:
Research Coordination
● To implement the system approach for research of ASCVD through analyses of genomics, epigenetic, transcriptomics, proteomics, and metabolomics traits related to lipid metabolism, inflammation, obesity, and blood pressure.
● To facilitate the development and optimization of novel products that will enable personalized prognostic, diagnostic and therapeutic approaches in ASCVD.
● To establish standardized pipelines for data integration based on machine learning (ML) and artificial intelligence (AI) approaches.
● To build a database of cohorts available for multi-centric omics studies.
● To develop pre-analytical, analytical, and post-analytical standard operative procedures (SOP) for genomic, epigenetic, transcriptomic, proteomic, and metabolomic markers related to ASCVD. Capacity Building
● To facilitate interdisciplinary scientific collaborations within the cardiovascular field by bringing together academic, clinical and industrial stakeholders.
● To build omics experts by acting as a platform for interdisciplinary dialog and knowledge transfer between researchers, clinicians and industrial partners
● To reduce inequalities in research by making available expensive techniques and equipment ensuring equal access to all the partners independently of their social, economic or gender status.
● To promote Early Career Investigators through involvement in decision-making activities of the Action.